The award is regarded as one of the most prestigious awards for early cancer innovations in Europe. It is awarded by a panel of leading oncology experts from nine international pharmaceutical companies. The decisive factor here is not only the scientific quality, but above all the potential to treat a previously insufficiently treatable disease more effectively in future. KyDo is developing novel active substances that are designed to specifically intervene in disease-relevant signalling pathways of cancer cells. The focus is on so-called covalent allosteric inhibitors. They promise greater efficacy with fewer side effects and could pave the way for new combination therapies. The company's roots lie in cutting-edge research. The underlying technology was developed at the Technical University of Dortmund and, together with several research institutions and the Lead Discovery Centre, was transferred to industrial drug development. KyDo is supported by an experienced consortium of investors that successfully completed a financing round as recently as 2025. The award emphasises the growing importance of German biotechnology in the international competition for innovation. While large pharmaceutical companies around the world are searching for new therapeutic approaches, many of the most promising ideas today originate in highly specialised start-ups. For KyDo, the award is therefore far more than just a scientific success. It is a strong signal that the technology developed has the potential to play a decisive role in shaping the path of new cancer drugs.
News of "KyDo Therapeutics GmbH" from 27.05.2026